Oncogenic studies with felbamate (2-phenyl-1,3-propanediol dicarbamate).
Felbamate, 2-phenyl-1,3-propanediol dicarbamate, is a novel anticonvulsant that is effective against both chemically and electrically induced seizures in laboratory animals. Oncogenic studies were conducted in mice and rats to establish a preclinical safety profile for this drug. There was an increased incidence of hepatic cell adenoma in male and female mice and in female rats. There was an increased incidence of interstitial cell tumors of the testes in the male rat.
McGee
J H
JH
Wallace Laboratories, Cranbury, New Jersey 08512, USA.
Butler
W H
WH
Erikson
D J
DJ
Sofia
R D
RD
D018248:Adenoma, Liver Cell / Q000139:chemically induced; D000284:Administration, Oral; D000818:Animals; D000927:Anticonvulsants / Q000097:blood / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D015197:Carcinogenicity Tests; D000078328:Felbamate; D005260:Female; D007984:Leydig Cell Tumor / Q000139:chemically induced; D008113:Liver Neoplasms / Q000139:chemically induced; D008297:Male; D051379:Mice; D018696:Neuroprotective Agents / Q000097:blood / Q000633:toxicity*; D048448:Phenylcarbamates; D011409:Propylene Glycols / Q000097:blood / Q000633:toxicity*; D051381:Rats; D013736:Testicular Neoplasms / Q000139:chemically induced
D000927:Anticonvulsants; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D011409:Propylene Glycols; D000078328:Felbamate